Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LAVA-051 in relapsed or refractory CLL, multiple myeloma, or AML
NL-OMON51940Phase 1Recruiting
- Sponsor
- LAVA Therapeutics
- Start
- Jun 2021
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of LAVA-051 in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), multiple myeloma (MM) and acute myeloid leukemia (AML), sponsored by LAVA Therapeutics. Primary endpoints: Frequency and severity of adverse events in dose escalation, Dose-limiting toxicities and 1 more. Started Jun 2021; status: recruiting.
02
Drugs
LAVA-051
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)multiple myeloma (MM)acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NL-OMON51940.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON51940.